Lupin, a global pharmaceutical giant, proudly announces the reception of the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its manufacturing facility in Aurangabad. Conducted from March 6 to March 15, 2024, the inspection resulted in the facility receiving a Voluntary Action Indicated (VAI) classification from the U.S. FDA.
Nilesh Gupta, Managing Director of Lupin, expressed delight at the EIR’s issuance with VAI status, highlighting it as a reflection of Lupin’s unwavering dedication to maintaining top-notch compliance standards and delivering premium healthcare solutions worldwide.
Headquartered in Mumbai, India, Lupin stands as an innovation-driven multinational pharmaceutical enterprise. Its extensive portfolio encompasses branded and generic formulations, biotechnology products, and APIs distributed across more than 100 markets spanning the U.S., India, South Africa, Asia Pacific (APAC), Latin America (LATAM), Europe, and the Middle East.
Lupin’s dominance extends to key therapeutic segments such as cardiovascular, anti-diabetic, and respiratory categories, supplemented by a strong presence in anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health sectors. Notably, Lupin holds the esteemed position of being the third-largest pharmaceutical company in the U.S. by prescriptions. Demonstrating its commitment to innovation, the company allocated 7.9% of its revenue to research and development endeavors in FY23.
With 15 manufacturing sites, 7 research centers, and a workforce exceeding 20,000 professionals worldwide, Lupin consistently earns accolades as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.
